PBRM1 and renal cell carcinoma: Additionally, the previous study found that only patients with renal cell carcinoma and SWI/SNF-LOF mutations showed significantly improved survival in the cohort from Dana Farber Cancer Institute, which was mostly driven by PRBM1. Similarly, we found that PBRM1 mutations were associated with a better outcome of ICI treatments than the other SWI/SNF gene mutations (Fig. 4b).